Clinical Colorectal Cancer
IF
4.48
Papers
1,317
Papers 1,290
1 page of 129 pages (1,290 results)
Newest
#1David D. B. Bates (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
#2Maria El Homsi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Shannon P. Sheedy (Mayo Clinic)H-Index: 11
view all 6 authors...
Abstract null null Rectal cancer is a relatively common malignancy in the United States. Magnetic resonance imaging (MRI) of rectal cancer has evolved tremendously in recent years, and has become a key component of baseline staging and treatment planning. In addition to assessing the primary tumor and locoregional lymph nodes, rectal MRI can be used to help with risk stratification by identifying high risk features such as extramural vascular invasion and can assess treatment response for patien...
Source
#1Yufei Yang (Fudan University)H-Index: 5
#2Dakui Luo (Fudan University)H-Index: 7
Last. Xinxiang Li (Fudan University)H-Index: 19
view all 6 authors...
Abstract null null The prognostic value of tumor regression grade (TRG) in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation therapy has been explored extensively. However, whether TRG is predictive of outcome in colon cancer following preoperative chemotherapy has not been reported. A total of 276 colon cancer patients who had undergone preoperative chemotherapy and surgery in Fudan University Shanghai Cancer Center during the period March 2014 through Novembe...
Source
#1Sweet Ping Ng (La Trobe University)H-Index: 1
#2Samuel Y. Ngan (University of Melbourne)H-Index: 28
Last. Trevor Leong (University of Melbourne)H-Index: 26
view all 3 authors...
Abstract null null Colorectal cancer is the 3rd most commonly diagnosed cancer, with rectal cancer accounting for 30% of cases. The current standard of care curative treatment for locally advanced rectal cancer is (chemo)radiotherapy followed by surgery and adjuvant chemotherapy. Although neoadjuvant radiotherapy has reduced the risk of local recurrence to less than 10%, the risk of distant metastasis remained high at 30% affecting patient survival. In addition, there is a recognition that there...
Source
#1Joseph Sia (Peter MacCallum Cancer Centre)H-Index: 5
#2Wei Mou (Peter MacCallum Cancer Centre)
Last. Samuel Y. Ngan (Peter MacCallum Cancer Centre)H-Index: 28
view all 10 authors...
Background null To analyze the long-term outcomes and prognostic value of hematological parameters in anal cancer patients receiving intensity-modulated radiation therapy (IMRT). null Materials null Hospital records of consecutive patients with anal squamous cell carcinoma who received curative-intent IMRT according to a standardized contouring protocol between 2010 and 2020 were reviewed. Locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), progression-free surviv...
Source
#1Romy Aarnoutse (UM: Maastricht University)H-Index: 3
#2Janine Ziemons (UM: Maastricht University)H-Index: 4
Last. Marjolein L. Smidt (MUMC: Maastricht University Medical Centre)H-Index: 30
view all 14 authors...
Abstract null null Background null Intestinal microbiota might interact with capecitabine and vice versa. null null null Patients and methods null 33 mCRC patients collected faecal samples before, during, and after three cycles capecitabine. null null null Results null Intestinal microbiota were not affected by capecitabine and not different between responders and non-responders. null null null Conclusions null Our study provides insights into challenges and points of attention for the design of...
Source
Clinical Practice Points null null null null • null null Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of oxaliplatin-based chemotherapy. null null • null null Nodular regenerative hyperplasia can be associated at a late stage of SOS, and should be suspected in case of signs of portal hypertension such as thrombocytopenia or splenomegaly. null null • null null To our knowledge, this is the first report of SOS occurring after oxaliplatin hepatic arterial infusion (HAI)....
Source
Neuroendocrine tumors (NETs) are slow-growing malignancies with distinct biologic and clinical characteristics. Most rectal-NETs are localized and well-differentiated, usually carrying an excellent prognosis. In this review, we aim at describing the epidemiology, clinical characteristics and therapeutic approaches for well-differentiated rectal NETs.
Source
#1Hideaki BandoH-Index: 21
#2Yuichiro TsukadaH-Index: 8
Last. Takayuki YoshinoH-Index: 57
view all 4 authors...
Chemoradiotherapy (CRT) followed by radical surgery is one of the standard therapies for patients with locally advanced rectal cancer (LARC). Various combination therapies have been developed to improve the efficacy of preoperative therapies. One promising approach is the combination of ionizing radiation and immune checkpoint inhibitors (ICIs) because it enhances both local and distal immunogenic efficacy according to several xenograft models. To date, promising short-term efficacy results of 2...
Source
#1Nicolette Taku (The University of Texas MD Anderson Cancer Center)H-Index: 5
#2Y. Nancy Yi-Qian (The University of Texas MD Anderson Cancer Center)
Last. Prajnan Das (The University of Texas MD Anderson Cancer Center)H-Index: 52
view all 21 authors...
Abstract null null Purpose null There has been an increase in the incidence of rectal cancer diagnosed in young adults (age null null null null Methods null The medical records of 219 patients, age 18-49, with non-metastatic, cT3-4, or cN1-2 rectal adenocarcinoma treated from 2000-2017 were reviewed for demographic and treatment characteristics, as well as pathologic and oncologic outcomes. Kaplan-Meier test, log-rank test, and Cox regression analysis were used to evaluate survival outcomes. nul...
Source
#1Aurélie BertautH-Index: 18
#2Yann TouchefeuH-Index: 17
Last. Jaafar BennounaH-Index: 59
view all 12 authors...
Abstract null null Background and objectives null : We have previously showed that for patients with wild-type RAS metastatic colorectal cancer (mCRC) progressing after bevacizumab plus chemotherapy, bevacizumab continuation plus a switch of chemotherapy is the most appropriate option (PRODIGE 18 phase II study). Here we aimed to determine treatment impact in patient's Health-Related Quality Of Life (HRQoL) in PRODIGE18 study. null null null Methods null : HRQoL was evaluated in two arms bevaciz...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.